US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Mirati Therapeutics, Inc. - Common Stock
(NQ:
MRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirati Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
December 10, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Investigation Announced for Long-Term Investors in Mirati Therapeutics, Inc. (NASDAQ:MRTX)
↗
December 07, 2021
San Diego, CA -- (SBWIRE) -- 12/07/2021 -- Certain directors of Mirati Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
Topics
Regulatory Compliance
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer
November 22, 2021
From
Verastem Oncology
Via
Business Wire
Expert Ratings For Mirati Therapeutics
↗
November 19, 2021
Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst rating...
Via
Benzinga
Expert Ratings For Mirati Therapeutics
↗
September 21, 2021
Over the past 3 months, 5 analysts have published their opinion on Mirati Therapeutics (NASDAQ:
Via
Benzinga
New CEO At Mirati Therapeutics
↗
September 20, 2021
Amid data readouts from adagrasib, sitravatinib programs, Mirati Therapeutics Inc (NASDAQ: MRTX) has appointed David Meek as Chief Executive Officer,...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
↗
November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:
Via
Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
↗
November 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...
Via
Benzinga
Mirati Posts More Responses For Adagrasib-Keytruda Combo In Lung Cancer Setting
↗
November 09, 2021
In its Q3 earnings release, Mirati Therapeutics Inc (NASDAQ: MRTX) posted preliminary results from the Phase 1b cohort of the KRYSTAL-1 study evaluating adagrasib...
Via
Benzinga
NASDAQ:MRTX Investor Notice: Investigation over Possible Securities Laws Violations by Mirati Therapeutics, Inc.
↗
November 08, 2021
San Diego, CA -- (SBWIRE) -- 11/08/2021 -- Mirati Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Topics
Regulatory Compliance
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
↗
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
Mid-Afternoon Market Update: loanDepot Surges After Q3 Results; Mirati Therapeutics Shares Slide
↗
November 01, 2021
Toward the end of trading Monday, the Dow traded up 0.12% to 35,863.70 while the NASDAQ rose 0.18% to 15,525.52. The S&P, however, fell 0.10% to 4,600.81. The U.S. has the...
Via
Benzinga
Topics
Stocks
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
↗
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
November 01, 2021
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's regular session. As of 12:30 EST, this security is trading at a volume...
Via
Benzinga
Earnings Scheduled For November 8, 2021
↗
November 08, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...
Via
Benzinga
64 Biggest Movers From Yesterday
↗
November 02, 2021
Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares climbed 137.4% to close at $6.03 on Monday on abnormally-high volume. The stock is seeing increased interest by traders on...
Via
Benzinga
Mid-Day Market Update: Dow Rises 50 Points; ANI Pharmaceuticals Shares Jump
↗
November 01, 2021
Midway through trading Monday, the Dow traded up 0.14% to 35,871.27 while the NASDAQ rose 0.23% to 15,534.49. The S&P also fell, dropping 0.03% to 4,603.98. The U.S. has the...
Via
Benzinga
Topics
Stocks
40 Stocks Moving In Monday's Mid-Day Session
↗
November 01, 2021
Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares jumped 250% to $8.91 on abnormally-high volume. The stock is seeing increased interest by traders on social media. Also, the...
Via
Benzinga
Mirati Therapeutics COO, CMO Exit, Completing Management Overhaul
↗
November 01, 2021
Shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) are retreating sharply Monday following two executive departures. What Happened: Mirati, a clinical-stage targeted oncology...
Via
Benzinga
Here's My Top Value Stock To Buy Right Now
↗
November 01, 2021
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications.
Via
Talk Markets
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
↗
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
↗
October 06, 2021
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal...
Via
Benzinga
What 6 Analyst Ratings Have To Say About Mirati Therapeutics
↗
September 23, 2021
Over the past 3 months, 6 analysts have published their opinion on Mirati Therapeutics (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
↗
September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:
Via
Benzinga
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
↗
September 21, 2021
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
↗
September 21, 2021
RBC Capital boosted MSCI Inc. (NYSE:MSCI) price tar...
Via
Benzinga
Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer
↗
September 20, 2021
Mirati Therapeutics easily beat Amgen's test results in colon cancer.
Via
Investor's Business Daily
Why Mirati Therapeutics Stock Is Trading Higher Today
↗
September 20, 2021
Mirati Therapeutics Inc (NASDAQ: MRTX) is trading higher Monday after the company announced clinical data with investigational adagrasib as monotherapy and in combination...
Via
Benzinga
35 Stocks Moving In Monday's Mid-Day Session
↗
September 20, 2021
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. (NASDAQ: EDSA) jumped 30.6% to $7.68 after the company...
Via
Benzinga
Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
↗
September 20, 2021
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500 of sitravatinib combined...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
